Clinical TrialsSearch results
Number of results: 215
- Recruitment status
- Title of the study
- Health Condition
- Primary sponsor
- Date of registration
Recruiting
- Depressive Episodes Associated with Bipolar I or II Disorder: A Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of ABBV-932
- Bipolar I Disorder Bipolar II Disorder
- Otani Tetsuya
- 2024-11-12
Recruiting
- Follow-up study
- Bladder cancer
- Fukuhara Hideo
- 2024-10-30
Not yet recruiting
- A study to test different doses of BI 1569912 in people with depression
- Major Depressive Disorder
- Taguchi Aya
- 2024-10-03
Recruiting
- A study to evaluate the efficacy and safety of subcutaneous amlitelimab monotherapy compared with placebo in adult participants with severe alopecia areata
- Alopecia areata
- Tanaka Tomoyuki
- 2024-07-07
Recruiting
- A study to evaluate the treatment response and safety of two dose regimens of subcutaneous amlitelimab monotherapy compared with treatment withdrawal in participants aged 12 years and older with moderate-to-severe atopic dermatitis
- Dermatitis atopic
- Tanaka Tomoyuki
- 2024-06-28
Recruiting
- Atopic Dermatitis: A Study of Upadacitinib in Adult Subjects with Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (SWITCH-UP)
- Atopic Dermatitis
- Otani Tetsuya
- 2024-06-21
Recruiting
- A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo
- NonSegmental Vitiligo
- Ono Shintaro
- 2024-06-14
Not yet recruiting
- Development of a Nursing Intervention Program
- pregnant women and families. Expected effect, Increased Family Confidence
- Iwasaki Junko
- 2024-05-24
Not yet recruiting
- The Impact of Sessions in Nursing Patients with Schizophrenia Comparison of Video Calls and Face-to-Face -Series of N-of-1 Trials-
- Schizophrenia or schizoaffective disorder according to DSM-5 or ICD-11 diagnostic criteria
- Komatsubara Daisuke
- 2024-05-15
Recruiting
- A study to evaluate the efficacy and safety of subcutaneous amlitelimab on background topical corticosteroids therapy in participants aged 12 years and older with moderate-to-severe AD who have had an inadequate response to prior biologic therapy or an oral JAK inhibitor
- Dermatitis atopic
- Tanaka Tomoyuki
- 2024-05-08